Symbols / INTS
INTS Chart
About
Intensity Therapeutics, Inc., a late-stage clinical biotechnology company, engages in the provision of treatment for the regional and systemic nature of cancer in the United States. Its lead product candidate includes INT230-6, which is in Phase 3 clinical studies for the treatment of soft tissue sarcoma; and neoadjuvant and metastatic triple negative breast cancer which is in Phase 2 clinical trials. The company was incorporated in 2012 and is headquartered in Shelton, Connecticut.
Fundamentals
Scroll to Statements| Sector | Healthcare | Industry | Biotechnology | Market Cap | 17.23M |
| Enterprise Value | 9.39M | Income | -11.74M | Sales | — |
| Book/sh | 3.68 | Cash/sh | 2.94 | Dividend Yield | — |
| Payout | 0.00% | Employees | 5 | IPO | — |
| P/E | — | Forward P/E | -1.24 | PEG | — |
| P/S | — | P/B | 1.85 | P/C | — |
| EV/EBITDA | — | EV/Sales | — | Quick Ratio | 3.10 |
| Current Ratio | 3.60 | Debt/Eq | 1.63 | LT Debt/Eq | — |
| EPS (ttm) | -13.75 | EPS next Y | -5.50 | EPS Growth | — |
| Revenue Growth | — | Earnings | 2025-11-06 16:00 | ROA | -101.66% |
| ROE | -234.70% | ROIC | — | Gross Margin | 0.00% |
| Oper. Margin | 0.00% | Profit Margin | 0.00% | Shs Outstand | 2.53M |
| Shs Float | 2.20M | Short Float | 2.00% | Short Ratio | 0.92 |
| Short Interest | — | 52W High | 62.50 | 52W Low | 4.62 |
| Beta | 4.22 | Avg Volume | 85.50K | Volume | 108.87K |
| Target Price | $72.50 | Recom | None | Prev Close | $5.84 |
| Price | $6.80 | Change | 16.44% |
Valuation Models
Price estimates from analyst targets and simple models.
1. Analyst consensus
$72.50
Mean price target
2. Current target
$6.80
Latest analyst target
3. DCF / Fair value
$-37.36
Simplified: (Free Cash Flow ÷ Shares) × 18 (P/FCF multiple). Not a …
Ratings
Current target
$6.80
Low
$37.50
High
$125.00
Mean
$72.50
Latest analyst rating changes
| Date | Action | Analyst | Rating Change | Price Target |
|---|---|---|---|---|
| 2025-08-20 | main | Benchmark | Speculative Buy → Speculative Buy | $2 |
| 2025-08-12 | up | Brookline Capital | Hold → Buy | $3 |
| 2025-01-13 | init | Alliance Global Partners | — → Buy | $9 |
| 2024-11-21 | reit | HC Wainwright & Co. | Buy → Buy | $5 |
| 2024-10-31 | init | HC Wainwright & Co. | — → Buy | $5 |
| 2024-07-11 | reit | Benchmark | Speculative Buy → Speculative Buy | $12 |
| 2024-05-16 | reit | Benchmark | Speculative Buy → Speculative Buy | $12 |
| 2024-03-21 | reit | Benchmark | Speculative Buy → Speculative Buy | $12 |
| 2023-11-14 | reit | Benchmark | Speculative Buy → Speculative Buy | $12 |
| 2023-08-24 | reit | Benchmark | Speculative Buy → Speculative Buy | $12 |
| 2023-07-18 | init | Benchmark | — → Speculative Buy | $12 |
- Intensity Therapeutics Announces Reverse Stock Split - PR Newswire Fri, 13 Feb 2026 08
- All You Need to Know About Intensity Therapeutics Inc. (INTS) Rating Upgrade to Buy - Yahoo Finance Mon, 15 Dec 2025 08
- Why Did INTS Stock Plummet 25% Today? - Stocktwits Sun, 15 Feb 2026 14
- Why Is Intensity Therapeutics Stock (INTS) Up 195% Today? - TipRanks hu, 30 Oct 2025 07
- Intensity Therapeutics stock soars after phase 1/2 data publication - Investing.com hu, 30 Oct 2025 07
- Intensity Therapeutics (Nasdaq: INTS) Stock: Announces 1-for-25 Reverse Split to Meet Nasdaq Rule - CoinCentral Fri, 13 Feb 2026 18
- Intensity Therapeutics, Inc. Announces Pricing of $4 Million Registered Direct Offering of Common Stock - PR Newswire Fri, 31 Oct 2025 07
- Market Movers | Winners: FGNX, RIME, ATOM | Losers: POAS, PFSA, INTS - Trefis Sat, 14 Feb 2026 05
- What's Going On With Intensity Therapeutics Stock Friday? - Benzinga Fri, 13 Feb 2026 17
- Intensity Therapeutics stock tumbles after pricing $4 million offering - Investing.com Fri, 31 Oct 2025 07
- Why Is Retail Going Gaga Over INTS Stocks Today? - Stocktwits hu, 30 Oct 2025 15
- Intensity Therapeutics stock rises after securing Nasdaq listing extension - Investing.com Fri, 05 Dec 2025 08
- Intensity Therapeutics Reports Second Quarter 2025 Financial Results and Provides Corporate Update - PR Newswire hu, 07 Aug 2025 07
- Intensity Therapeutics stock up nearly 400% on solid tumour data - Clinical Trials Arena Fri, 31 Oct 2025 07
- Intensity Therapeutics Announces 1-for-25 Reverse Stock Split - TipRanks Fri, 13 Feb 2026 08
Insider Transactions
| Date | Shares | Value | Url | Text | Insider | Position | Transaction | Start Date | Ownership |
|---|---|---|---|---|---|---|---|---|---|
| 0 | 14482 | 5941 | — | Stock Award(Grant) at price 0.41 per share. | TALAMO JOSEPH CPA | Chief Financial Officer | — | 2025-12-31 00:00:00 | D |
| 1 | 8918 | 3658 | — | Stock Award(Grant) at price 0.41 per share. | WESOLOWSKI JOHN M CPA | Officer | — | 2025-12-31 00:00:00 | D |
| 2 | 14179 | 3701 | — | Stock Award(Grant) at price 0.26 per share. | TALAMO JOSEPH CPA | Chief Financial Officer | — | 2025-06-30 00:00:00 | D |
| 3 | 69745 | 18203 | — | Stock Award(Grant) at price 0.26 per share. | WESOLOWSKI JOHN M CPA | Officer | — | 2025-06-30 00:00:00 | D |
| 4 | 1000 | 4000 | — | Conversion of Exercise of derivative security at price 4.00 per share. | WESOLOWSKI JOHN M CPA | Officer | — | 2024-06-05 00:00:00 | D |
Financials
| Line Item | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| TaxEffectOfUnusualItems | 0.00 | 0.00 | 0.00 | 0.00 |
| TaxRateForCalcs | 0.00 | 0.00 | 0.00 | 0.00 |
| NormalizedEBITDA | -16.27M | -7.97M | -7.50M | -7.88M |
| TotalUnusualItems | 0.00 | -2.26M | 0.00 | |
| TotalUnusualItemsExcludingGoodwill | 0.00 | -2.26M | 0.00 | |
| NetIncomeFromContinuingOperationNetMinorityInterest | -16.27M | -10.54M | -7.58M | -7.90M |
| EBITDA | -16.27M | -10.23M | -7.50M | -7.88M |
| EBIT | -16.27M | -10.23M | -7.50M | -7.88M |
| NetInterestIncome | 314.00K | 19.00K | -80.00K | -14.16K |
| InterestExpense | 0.00 | 305.00K | 82.00K | 16.77K |
| InterestIncome | 314.00K | 324.00K | 2.00K | 2.61K |
| NormalizedIncome | -16.27M | -8.28M | -7.58M | -7.90M |
| NetIncomeFromContinuingAndDiscontinuedOperation | -16.27M | -10.54M | -7.58M | -7.90M |
| TotalExpenses | 16.59M | 8.32M | 7.55M | 8.00M |
| RentExpenseSupplemental | 142.00K | 153.00K | ||
| TotalOperatingIncomeAsReported | -16.59M | -8.32M | -7.55M | -8.01M |
| DilutedAverageShares | 13.91M | 8.62M | 13.10M | 13.10M |
| BasicAverageShares | 13.91M | 8.62M | 3.46M | 13.10M |
| DilutedEPS | -1.17 | -1.38 | -2.19 | -0.60 |
| BasicEPS | -1.17 | -1.38 | -2.19 | -0.60 |
| DilutedNIAvailtoComStockholders | -16.27M | -11.86M | -7.58M | -7.90M |
| NetIncomeCommonStockholders | -16.27M | -11.86M | -7.58M | -7.90M |
| PreferredStockDividends | 1.32M | |||
| NetIncome | -16.27M | -10.54M | -7.58M | -7.90M |
| NetIncomeIncludingNoncontrollingInterests | -16.27M | -10.54M | -7.58M | -7.90M |
| NetIncomeContinuousOperations | -16.27M | -10.54M | -7.58M | -7.90M |
| PretaxIncome | -16.27M | -10.54M | -7.58M | -7.90M |
| OtherIncomeExpense | 3.00K | -2.24M | 48.00K | 115.51K |
| OtherNonOperatingIncomeExpenses | 3.00K | 24.00K | 48.00K | 115.51K |
| SpecialIncomeCharges | 0.00 | -2.26M | 0.00 | |
| OtherSpecialCharges | 2.26M | |||
| NetNonOperatingInterestIncomeExpense | 314.00K | 19.00K | -80.00K | -14.16K |
| InterestExpenseNonOperating | 0.00 | 305.00K | 82.00K | 16.77K |
| InterestIncomeNonOperating | 314.00K | 324.00K | 2.00K | 2.61K |
| OperatingIncome | -16.59M | -8.32M | -7.55M | -8.00M |
| OperatingExpense | 16.59M | 8.32M | 7.55M | 8.00M |
| ResearchAndDevelopment | 10.50M | 4.79M | 5.13M | 5.86M |
| SellingGeneralAndAdministration | 6.09M | 3.53M | 2.42M | 2.14M |
| GeneralAndAdministrativeExpense | 6.09M | 3.53M | 2.42M | 2.14M |
| OtherGandA | 2.50M | 1.68M | 1.64M | 1.37M |
| InsuranceAndClaims | 874.00K | 608.00K | 75.00K | 71.00K |
| RentAndLandingFees | 142.00K | 153.00K | ||
| SalariesAndWages | 2.72M | 1.24M | 705.00K | 545.00K |
| TotalRevenue | 0.00 | 0.00 | 0.00 | 0.00 |
| OperatingRevenue | 0.00 | 0.00 | 0.00 | 0.00 |
| Line Item | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| OrdinarySharesNumber | 15.12M | 13.71M | 13.10M | 13.10M |
| ShareIssued | 15.12M | 13.71M | 13.10M | 13.10M |
| NetDebt | 3.04M | |||
| TotalDebt | 138.00K | 158.00K | 4.49M | 2.34M |
| TangibleBookValue | 2.92M | 13.16M | -15.10M | -8.68M |
| InvestedCapital | 2.92M | 13.16M | -10.75M | -6.67M |
| WorkingCapital | 1.61M | 11.51M | -5.37M | 1.01M |
| NetTangibleAssets | 2.92M | 13.16M | -15.10M | -8.68M |
| CapitalLeaseObligations | 138.00K | 158.00K | 143.00K | 325.91K |
| CommonStockEquity | 2.92M | 13.16M | -15.10M | -8.68M |
| PreferredStockEquity | 325.00 | 325.00 | ||
| TotalCapitalization | 2.92M | 13.16M | -15.10M | -8.68M |
| TotalEquityGrossMinorityInterest | 2.92M | 13.16M | -15.10M | -8.68M |
| StockholdersEquity | 2.92M | 13.16M | -15.10M | -8.68M |
| RetainedEarnings | -66.78M | -50.52M | -38.65M | -31.07M |
| AdditionalPaidInCapital | 69.70M | 63.68M | 23.55M | 22.39M |
| CapitalStock | 2.00K | 1.00K | 0.00 | 666.00 |
| CommonStock | 2.00K | 1.00K | 0.00 | 341.00 |
| PreferredStock | 0.00 | 0.00 | 0.00 | 325.00 |
| TotalLiabilitiesNetMinorityInterest | 1.86M | 4.13M | 16.86M | 13.90M |
| TotalNonCurrentLiabilitiesNetMinorityInterest | 110.00K | 174.00K | 10.04M | 10.18M |
| OtherNonCurrentLiabilities | 36.00K | 36.00K | 36.00K | |
| PreferredSecuritiesOutsideStockEquity | 0.00 | 10.00M | 10.00M | |
| LongTermDebtAndCapitalLeaseObligation | 110.00K | 138.00K | 0.00 | 143.57K |
| LongTermCapitalLeaseObligation | 110.00K | 138.00K | 0.00 | 143.57K |
| CurrentLiabilities | 1.75M | 3.96M | 6.82M | 3.72M |
| CurrentDebtAndCapitalLeaseObligation | 28.00K | 20.00K | 4.49M | 2.20M |
| CurrentCapitalLeaseObligation | 28.00K | 20.00K | 143.00K | 182.34K |
| CurrentDebt | 4.35M | 2.02M | ||
| OtherCurrentBorrowings | 4.35M | 2.02M | ||
| PensionandOtherPostRetirementBenefitPlansCurrent | 56.00K | 392.00K | ||
| PayablesAndAccruedExpenses | 1.67M | 3.55M | 2.33M | 1.52M |
| CurrentAccruedExpenses | 452.00K | 499.00K | 1.72M | 1.35M |
| Payables | 1.22M | 3.05M | 603.00K | 172.51K |
| AccountsPayable | 1.22M | 3.05M | 603.00K | 172.51K |
| TotalAssets | 4.78M | 17.30M | 1.76M | 5.22M |
| TotalNonCurrentAssets | 1.42M | 1.83M | 306.00K | 485.86K |
| OtherNonCurrentAssets | 1.30M | 1.68M | 167.00K | 167.74K |
| NonCurrentPrepaidAssets | 167.74K | 167.74K | ||
| NetPPE | 122.00K | 147.00K | 139.00K | 318.13K |
| GrossPPE | 122.00K | 147.00K | 139.00K | 318.13K |
| OtherProperties | 122.00K | 147.00K | 139.00K | 318.13K |
| CurrentAssets | 3.36M | 15.46M | 1.45M | 4.73M |
| OtherCurrentAssets | 6.00K | 76.00K | 69.28K | |
| PrepaidAssets | 773.00K | 688.00K | 63.00K | 70.44K |
| Receivables | 62.30K | 51.26K | ||
| DuefromRelatedPartiesCurrent | 46.40K | 0.00 | ||
| TaxesReceivable | 15.90K | 51.26K | ||
| CashCashEquivalentsAndShortTermInvestments | 2.59M | 14.78M | 1.31M | 4.54M |
| OtherShortTermInvestments | 0.00 | 6.22M | 0.00 | |
| CashAndCashEquivalents | 2.59M | 8.56M | 1.31M | 4.54M |
| CashEquivalents | 2.16M | 8.19M | 0.00 | |
| CashFinancial | 428.00K | 367.00K | 1.31M |
| Line Item | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| FreeCashFlow | -15.22M | -7.21M | -5.48M | -6.83M |
| IssuanceOfDebt | 0.00 | 230.00K | 2.25M | 2.00M |
| IssuanceOfCapitalStock | 3.23M | 22.43M | 0.00 | 0.00 |
| EndCashPosition | 2.59M | 8.56M | 1.31M | 4.54M |
| BeginningCashPosition | 8.56M | 1.31M | 4.54M | 9.32M |
| ChangesInCash | -5.97M | 7.24M | -3.23M | -4.78M |
| FinancingCashFlow | 2.90M | 20.47M | 2.25M | 2.05M |
| CashFlowFromContinuingFinancingActivities | 2.90M | 20.47M | 2.25M | 2.05M |
| NetOtherFinancingCharges | -653.00K | -2.23M | 50.00K | |
| ProceedsFromStockOptionExercised | 321.00K | 50.00K | 0.00 | |
| NetPreferredStockIssuance | 0.00 | |||
| PreferredStockIssuance | 0.00 | |||
| NetCommonStockIssuance | 3.23M | 22.43M | 0.00 | |
| CommonStockIssuance | 3.23M | 22.43M | 0.00 | |
| NetIssuancePaymentsOfDebt | 0.00 | 230.00K | 2.25M | 2.00M |
| NetShortTermDebtIssuance | 0.00 | 230.00K | 2.25M | 2.00M |
| ShortTermDebtIssuance | 0.00 | 230.00K | 2.25M | 2.00M |
| InvestingCashFlow | 6.35M | -6.02M | 0.00 | 0.00 |
| CashFlowFromContinuingInvestingActivities | 6.35M | -6.02M | 0.00 | 0.00 |
| NetInvestmentPurchaseAndSale | 6.35M | -6.02M | 0.00 | 0.00 |
| SaleOfInvestment | 9.41M | 9.03M | 0.00 | 0.00 |
| PurchaseOfInvestment | -3.06M | -15.05M | 0.00 | 0.00 |
| OperatingCashFlow | -15.22M | -7.21M | -5.48M | -6.83M |
| CashFlowFromContinuingOperatingActivities | -15.22M | -7.21M | -5.48M | -6.83M |
| ChangeInWorkingCapital | -1.97M | -436.00K | 757.00K | 176.80K |
| ChangeInOtherCurrentLiabilities | -182.69K | -171.57K | ||
| ChangeInOtherCurrentAssets | 52.53K | -15.15K | ||
| ChangeInPayablesAndAccruedExpense | -2.27M | 1.63M | 704.00K | 363.53K |
| ChangeInAccruedExpense | -197.00K | 0.00 | 413.73K | |
| ChangeInInterestPayable | -197.00K | 0.00 | 16.77K | |
| ChangeInPayable | -2.27M | 1.63M | 704.00K | -50.20K |
| ChangeInAccountPayable | -2.27M | 1.63M | 704.00K | -50.20K |
| ChangeInPrepaidAssets | 301.00K | -2.07M | 53.00K | |
| OtherNonCashItems | -58.00K | 109.00K | 179.00K | 172.11K |
| StockBasedCompensation | 3.07M | 1.40M | 1.17M | 719.82K |
| OperatingGainsLosses | 2.26M | |||
| NetIncomeFromContinuingOperations | -16.27M | -10.54M | -7.58M | -7.90M |
SEC Filings
Recent 10-K, 10-Q, 8-K, and Form 4 (insider) filings.
Public Trades for INTS
| Date | User | Asset | Broker | Type | Position Size | Entry Price | Patterns |
|---|